236 related articles for article (PubMed ID: 22757683)
1. Difficult clinical challenges in haemophilia: international experiential perspectives.
Forsyth AL; Giangrande P; Hay CR; Kenet G; Kessler CM; Knöbl PN; Llinás A; Santagostino E; Young G
Haemophilia; 2012 Jul; 18 Suppl 5():39-45. PubMed ID: 22757683
[TBL] [Abstract][Full Text] [Related]
2. Spondylodiscitis from infection of central venous line inserted for haemophilia prophylaxis.
Thachil J; Pillai A; Martlew V
Ann Hematol; 2012 Jul; 91(7):1151-2. PubMed ID: 22109799
[No Abstract] [Full Text] [Related]
3. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
Mancuso ME; Graca L; Auerswald G; Santagostino E
Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
5. Central venous access catheters in children with haemophilia.
Blanchette VS; al-Musa A; Stain AM; Filler RM; Ingram J
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S39-44. PubMed ID: 8735796
[TBL] [Abstract][Full Text] [Related]
6. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.
den Uijl IE; Fischer K
Thromb Haemost; 2008 May; 99(5):965; author reply 966-8. PubMed ID: 18449430
[No Abstract] [Full Text] [Related]
7. Fatal central venous catheter-related infection in haemophilia.
Crary SE; Buchanan GR; Journeycake JM
Haemophilia; 2006 Mar; 12(2):183-6. PubMed ID: 16476095
[TBL] [Abstract][Full Text] [Related]
8. Prevention of arthropathy in haemophilia: prophylaxis.
Santagostino E; Mancuso ME
Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
[TBL] [Abstract][Full Text] [Related]
9. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
[TBL] [Abstract][Full Text] [Related]
10. How I treat inhibitors in haemophilia.
Makris M; Hay CR; Gringeri A; D'Oiron R
Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083
[TBL] [Abstract][Full Text] [Related]
11. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
12. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience.
Auerswald G; Bidlingmaier C; Kurnik K
Haemophilia; 2012 Jan; 18(1):e18-20. PubMed ID: 21951822
[No Abstract] [Full Text] [Related]
13. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States.
Thornburg CD; Carpenter S; Zappa S; Munn J; Leissinger C
Haemophilia; 2012 Jul; 18(4):568-74. PubMed ID: 22335526
[TBL] [Abstract][Full Text] [Related]
14. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
15. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.
Kurnik K; Bidlingmaier C; Engl W; Chehadeh H; Reipert B; Auerswald G
Haemophilia; 2010 Mar; 16(2):256-62. PubMed ID: 19878331
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.
Mancuso ME; Mannucci PM; Sartori A; Agliardi A; Santagostino E
Br J Haematol; 2008 May; 141(5):689-95. PubMed ID: 18410458
[TBL] [Abstract][Full Text] [Related]
17. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
[TBL] [Abstract][Full Text] [Related]
18. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
Manco-Johnson M
Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
[TBL] [Abstract][Full Text] [Related]
19. The use of central venous catheters in haemophilia patients.
Izzi G; Franchini M; Bonetti L; Tagliaferri A
Haemophilia; 2010 Jan; 16 Suppl 1():29-31. PubMed ID: 20059567
[TBL] [Abstract][Full Text] [Related]
20. Reduced early prophylaxis of children with haemophilia in a developing country, Turkey.
Celkan T; Ozdemir N
Haemophilia; 2011 Sep; 17(5):e840-1. PubMed ID: 21682819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
